Russell Investments Group, Ltd. Viridian Therapeutics, Inc.\De Transaction History

Russell Investments Group, Ltd.

$66.8 Billion
Q3 2024

A detailed history of Russell Investments Group, Ltd. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 442,334 shares of VRDN stock, worth $9.57 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

442,334

Previous 349,631 26.51%

Holding current value

$9.57 Million

Previous $4.55 Million 121.26%

% of portfolio

0.02%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$12.16 - $23.33 $1.13 Million - $2.16 Million	92,703 Added 26.51%	442,334 $10.1 Million
Q2 2024 Aug 08, 2024	BUY	$11.6 - $17.26 $325,090 - $483,711	28,025 Added 8.71%	349,631 $4.55 Million
Q1 2024 May 08, 2024	SELL	$17.09 - $23.82 $134,635 - $187,653	-7,878 Reduced 2.39%	321,606 $5.63 Million
Q4 2023 Feb 05, 2024	BUY	$11.12 - $22.5 $337,414 - $682,717	30,343 Added 10.14%	329,484 $7.18 Million
Q3 2023 Nov 13, 2023	BUY	$15.16 - $24.7 $2.97 Million - $4.83 Million	195,616 Added 188.96%	299,141 $4.59 Million
Q2 2023 Aug 10, 2023	BUY	$22.57 - $29.67 $424,090 - $557,499	18,790 Added 22.18%	103,525 $2.46 Million
Q1 2023 May 09, 2023	SELL	$25.04 - $37.6 $9,815 - $14,739	-392 Reduced 0.46%	84,735 $2.16 Million
Q4 2022 Feb 08, 2023	BUY	$18.78 - $29.74 $757,359 - $1.2 Million	40,328 Added 90.02%	85,127 $2.49 Million
Q3 2022 Nov 04, 2022	BUY	$10.7 - $25.5 $479,349 - $1.14 Million	44,799 New	44,799 $917,000

Others Institutions Holding VRDN

# of Institutions

176

Shares Held

76.5M

Call Options Held

566K

Put Options Held

357K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $863M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Account

Russell Investments Group, Ltd. Viridian Therapeutics, Inc.\De Transaction History